CN1699 Social
Sign Up Login
  • Home
    • People
    • Photos
    • Videos
    • Topics
    • Bookmarks
    • Who viewed me
  • Events
  • Services
    • MDLA Events Platform
    • MDLA Events
    • MDLA Events Services & Pricing
    • Media Services & Pricing
  • User Tools
    • FAQ
    • Questions
    • User Notes
    • Feedback
    • Advertise with Us
    • Languages
      • English
      • 中文
      • French
      • Português
      • Español
      • Arabic
      • Russian
  • About Us
    • Contact Us
CN1699 Social
  • Mary Grace N. Tamio
    Mary Grace N. Tamio   
    on February 04 2022 at 06:50 PM Edited public
    Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma

    #trametinib #ovariancarcinoma

    For more information | ⬇️
    https://cn1699.com/news/trametinib-represents-potential-new-standard-care-patients-recurrent-low-grade-serous-ovarian
    Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma | CN1699
    A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of...
    0 0 0 0 0 0 0
    comment Comment
    thumb_upLike
    share Share
    • No login
      gif
      Please login or register

Modal title

Modal title

CN1699 Mobile. Connect with people anytime, anywhere! Available for Android!

  • About Us
  • Terms of Service
  • Privacy Policy
  • Contact Us
  • Advertise with us
  • Feedback
  • English
  • 中文
  • French
  • Português
  • Español
  • Arabic
  • Russian

Copyright © 2024 CN1699 Social. All rights reserved English

Share

Login

Global News and Health Forum

Join Now!

Member Login

Remember me
Forgot password?